Estado del arte con el tratamiento con inhibidores de BRAF + MEK

4 / 116

Drugs approvals of EMA in advanced melanoma
Date of issue of marketing authorization for the European Union
• Ipilimumab* 13/07/2011 - 20/09/2013*
• Vemurafenib 17/02/2012
• Dabrafenib 28/06/2013
• Trametinib 30/06/2014
• Nivolumab 19/06/2015
• Pembrolizumab 17/07/2015
• Dabrafenib + Trametinib 23/07/2015
• Vemurafenib + Cobimetinib 20/11/2015
• Talimogene Laherparevec 16/12/2015
• Nivolumab + Ipilimumab 01/04/2016
• Encorafenib + Binimetinib 21/09/2018